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Abstract Epidermal and nerve growth factors (EGF and NGF)
activate protein synthesis and initiation factor eIF2B in rat
phaeochromocytoma (PC12) cells. The activation of protein
synthesis by EGF or NGF depends upon extracellular regulated
kinase kinase (MEK)/extracellular regulated kinase signalling.
Here we show that PD98059, an inhibitor of MEK activation,
blocks the activation of eIF2B by EGF or NGF. It is known that
eIF2B activity can be inhibited by phosphorylation at Ser535 in
its O-subunit by glycogen synthase kinase (GSK)-3. We find that
inactivation of GSK-3 by EGF or NGF is blocked by PD98059.
However, neither EGF nor NGF caused a detectable change in
phosphorylation of Ser535 of eIF2BO. Thus, the EGF- and NGF-
induced activation of eIF2B in PC12 cells involves regulatory
mechanisms distinct from dephosphorylation of the GSK-3
site. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Eukaryotic initiation factor (eIF)2B plays an important role
in the initiation of mRNA translation in eukaryotic cells and
in its control. eIF2B is a guanine nucleotide exchange factor
and catalyses the exchange of GDP for GTP on eIF2. When
complexed with GTP, eIF2 is in the active form and recruits
the initiator Met-tRNA, which is required for recognition of
the start codon, to the 40S subunit. The GTP is subsequently
hydrolysed, leading to release of inactive eIF2WGDP com-
plexes from the ribosome. In order to regenerate active
eIF2WGTP, which is required for all translation initiation
events, the GDP must be exchanged for GTP and this step
is mediated by eIF2B.
The activity of eIF2B may be regulated in several ways. The
best characterised mechanism involves phosphorylation of the
K-subunit of eIF2, which leads to eIF2(KP) becoming a potent
competitive inhibitor of eIF2B, and to inhibition of transla-
tion initiation [1]. Phosphorylation of the O-subunit of eIF2B
provides another mechanism for the regulation of the activity
of eIF2B. Phosphorylation by glycogen synthase kinase-3
(GSK-3) inhibits the activity of eIF2B [2,3], while phosphor-
ylation by casein kinase I or II is reported to increase eIF2B
activity [4,5]. Inactivation of GSK-3 coincides with the acti-
vation of eIF2B in insulin-stimulated CHO-T cells and epi-
dermal growth factor (EGF)- or nerve growth factor (NGF)-
treated rat phaeochromocytoma (PC12) cells [6,7]. Further-
more, GSK-3 is regulated through phosphatidylinositol 3-ki-
nase (PI 3-kinase) and a requirement for PI 3-kinase for the
activation of eIF2B has been shown in several studies [6,7]. In
addition, Ser540, the phosphorylation site for GSK-3 in eIF2-
BO, undergoes dephosphorylation in vivo after insulin stimu-
lation of CHO-T cells, and this is blocked by inhibitors of PI
3-kinase [3].
In our previous study [7], we described the regulation of
protein synthesis, the activation of eIF2B and the inactivation
of GSK-3 in response to EGF and NGF in PC12 phaeochro-
mocytoma cells. In these cells, activation of eIF2B and inac-
tivation of GSK-3 correlated with increased protein synthesis,
which were all inhibited by wortmannin. Recently, we discov-
ered that beside the PI 3-kinase dependent pathway, the acti-
vation of protein synthesis by EGF or NGF also involves
extracellular regulated kinase kinase (MEK)/extracellular
regulated kinase (ERK) signalling [8]. Given the previously
demonstrated correlation between protein synthesis and
eIF2B activation, we wished to examine the role of ERK
signalling in the regulation of the activation of eIF2B. Our
studies reveal, for the ¢rst time, that the MEK/ERK pathway
is required for activation of eIF2B in PC12 cells. Further-
more, MEK-dependent activation of eIF2B does not involve
changes in the phosphorylation state of the ‘priming site’,
Ser539, or dephosphorylation of Ser535, the phosphorylation
site for GSK-3 in rat eIF2BO.
2. Materials and methods
2.1. Cell culture
PC12 cells were maintained as described previously [8]. The cells
were grown to 60^70% con£uency, starved of serum for 2 h, followed
by treatment with EGF (50 ng/ml) or NGF (30 ng/ml) in the absence
or presence of PD98059 (50 WM) and harvested in the bu¡er appro-
priate for the assay.
2.2. Measurement of protein kinase B (PKB) kinase activity
Cells were treated with EGF or NGF and harvested as described
[8]. Antibodies directed against the three PKB isoforms, K, L and Q,
were bound simultaneously to protein G, and about 100 Wg of cell
extract was used for each immunoprecipitation reaction. The immu-
noprecipitation and the PKB assays were performed as described pre-
viously [9].
2.3. Measurement of eIF2B activity
The eIF2B assay was performed as described previously [7]. Brie£y,
the cells were harvested in a bu¡er containing 20 mM Tris^HCl pH
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7.5, 50 mM L-glycerophosphate, 100 mM KCl, 0.2 mM sodium or-
thovanadate, 0.2 mM EDTA, 0.2 mM EGTA, 1% Triton X-100, 10%
glycerol, 1 Wg/ml leupeptin, 1 Wg/ml pepstatin, 1 Wg/ml antipain, 1 mM
benzamidine and 1 mM DTT. Three Wg of cell extract was used in
each assay.
2.4. Measurement of GSK-3 activity
Antibodies against both the K- (Upstate Biotechnology Incorpo-
rated) and the L-isoforms (Transduction Laboratories) of GSK-3
were bound to protein G and used to immunoprecipitate GSK-3
from about 100 Wg of cell extract. GSK-3 activity was determined
as described [7], except that immunoprecipitated material, rather
than crude cell extracts, was used.
2.5. Analysis of the phosphorylation state of ERK
After treatment, cells were harvested in Laemmli sample bu¡er and
samples were analysed by sodium dodecyl sulphate^polyacrylamide
gel electrophoresis (SDS^PAGE) as described earlier [10]. ERK2 pro-
tein was detected by Western blotting with a polyclonal antibody
raised in sheep (a kind gift from Dr. Dario Alessi, Dundee, UK).
2.6. Phosphorylation of eIF2BO
Cell extracts (30 Wg) were analysed by SDS^PAGE and Western
blotting. Phosphorylation of Ser535 (which corresponds to Ser540 in
the rabbit sequence) in rat eIF2BO was monitored by using a phospho-
speci¢c antibody [3]. Phosphorylation of Ser539 (which corresponds
to Ser544 in the rabbit sequence), the ‘priming site’, was detected
using a phospho-speci¢c antibody. The speci¢c recognition of the
phosphorylated Ser539 was examined using eIF2BO that was either
phosphorylated at this site or not (Maarten Janmaat and Chris Proud,
unpublished observations). Equal loading was con¢rmed using an
antibody that detects eIF2B irrespective of its state of phosphoryla-
tion.
3. Results
3.1. Activation of eIF2B by NGF or EGF requires the ERK
pathway
PC12 cells were treated with EGF or NGF in the absence
or presence of the MEK inhibitor PD98059 (50 mM) and the
activity of eIF2B was measured. As described earlier [7], treat-
ment of PC12 cells with NGF or EGF led to activation of the
nucleotide-exchange activity of eIF2B (Fig. 1A). A speci¢c
inhibitor of MEK, PD98059, completely inhibited the ability
of EGF or NGF to activate eIF2B, without a¡ecting the basal
level of eIF2B activity in control cells. These data imply that
MEK, and thus ERK, signalling is required for the activation
of eIF2B by EGF and NGF in PC12 cells.
3.2. Two di¡erent pathways are involved in the regulation of
eIF2B
In order to verify that PD98059 does indeed block ERK
signalling in PC12 cells, we assessed the phosphorylation state
of ERK. Both EGF- and NGF-induced phosphorylation of
ERK2 in PC12 cells, as manifested by a shift in the electro-
phoretic mobility of ERK2 (Fig. 1B) [10,11]. As expected,
PD98059 completely blocked the phosphorylation of ERK2
in cells treated with either EGF or NGF.
It has been shown that in some cell lines wortmannin blocks
the activation of ERK [12,13]. Therefore, it was important to
establish that activation of eIF2B by EGF or NGF via a
MEK-dependent pathway is di¡erent from the wortmannin-
sensitive pathway previously described [7]. In PC12 cells, it
was previously shown that wortmannin only partially blocks
ERK phosphorylation [10]. We con¢rm this ¢nding (Fig. 1B)
when we treated the cells with EGF or NGF in the absence or
presence of wortmannin (20^40% inhibition), showing that the
e¡ect of wortmannin on the activation of eIF2B is mainly via
the PI 3-kinase pathway.
The PI 3-kinase dependent pathway involved in the regu-
lation of eIF2B activity is thought to include GSK-3. Because
PKB is a well-established regulator of GSK-3 [14,15], it was
also important to exclude the possibility that PD98059 af-
fected the activation of PKB by EGF or NGF to con¢rm
the speci¢city of this inhibitor. PKB was rapidly activated
after EGF or NGF treatment as reported earlier [8,16] and
this activation was not a¡ected by the MEK inhibitor
PD98059 (Fig. 2). Thus, PD98059 only a¡ects the MEK/
ERK pathway, while the e¡ect of wortmannin on the activa-
tion of eIF2B is mainly due to the PI 3-kinase pathway, in-
dicating that two separate pathways are involved in the reg-
ulation of eIF2B.
3.3. The inactivation of GSK-3 is blocked by PD98059
In PC12 cells, both EGF and NGF induce the inhibition of
GSK-3 concomitantly with the activation of eIF2B [7]. In
view of our ¢nding that the activation of eIF2B by these
stimuli is blocked by PD98059, we studied whether
PD98059 a¡ected the ability of EGF and NGF to inactivate
GSK-3 (Fig. 3A). As reported earlier [7], inactivation of GSK-
3 by EGF or NGF is modest (reduction in activity of about
20^30% versus the control). In the presence of PD98059, the
basal activity of GSK-3 was slightly reduced in control cells.
However, in the presence of PD98059, neither EGF nor NGF
Fig. 1. Activation of eIF2B by EGF or NGF is regulated in an
ERK-dependent manner. A: Cells were starved for serum and
treated with EGF (60 min) or NGF (90 min) in the absence (con-
trol) or presence (control+PD) of PD98059. The cells were har-
vested and an eIF2B assay was performed as described in Section 2.
Activation of eIF2B by EGF or NGF in the absence of PD98059 is
signi¢cantly di¡erent from activation of eIF2B in the presence of
PD98059 (P9 0.05). The eIF2B activity in control cells with no
growth factors added was set at 100%. The error bars represent the
standard error of the mean (n = 5). B: The cells were treated with
EGF for 5 min or with NGF for 10 min in the absence or presence
of PD98059 or in the absence or presence of wortmannin (100 nM).
The cells were harvested in Laemmli sample bu¡er and the lysates
were analysed by SDS^PAGE and Western blotting (n = 3). 3, no
addition; E, EGF added; N, NGF added. p42 and pp42 indicate,
respectively, unphosphorylated and phosphorylated ERK2.
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signi¢cantly a¡ected GSK-3 activity relative to the control
cells treated with PD98059. These data imply that ERK sig-
nalling is required for the inactivation of GSK-3 in response
to EGF or NGF in PC12 cells.
We have previously shown a correlation between the acti-
vation of eIF2B and inactivation of GSK-3. Both the kinetics
[7] and the pathways involved in the regulation were similar
after EGF or NGF treatment of PC12 cells. A phospho-spe-
ci¢c antibody for the GSK-3 phosphorylation site in eIF2BO,
Ser535 (Ser540 in the rabbit sequence), is now available.
Therefore, we wished to examine the phosphorylation state
of this residue in PC12 cells after EGF or NGF treatment
to show that GSK-3 does indeed play a role in the regulation
of eIF2B in these cells. However, we were unable to detect a
change in its phosphorylation at this site in response to EGF
or NGF (Fig. 3B). The basal level of phosphorylation of
Ser535 was also not a¡ected by PD98059 or wortmannin.
The only other identi¢ed phosphorylation site in eIF2Be is
Ser539. Using synthetic peptides, it was shown that this resi-
due (‘priming site’) needs to be phosphorylated before GSK-3
is able to phosphorylate Ser535 [17,18]. To assess its possible
role in regulating eIF2B activity, we examined whether phos-
phorylation of Ser539 was a¡ected by EGF or NGF treat-
ment. No change in the phosphorylation state of this site was
detected under these conditions. These data suggest that EGF
and NGF regulate eIF2B via a mechanism that does not in-
volve changes in the phosphorylation of Ser535 or Ser539 in
eIF2BO.
4. Discussion
This report shows for the ¢rst time that activation of MEK
is required for the stimulation of eIF2B speci¢cally in re-
sponse to EGF or NGF in PC12 cells. We have previously
shown that the activation of eIF2B required a wortmannin-
sensitive component. Our results show that PD98059 did not
a¡ect PKB activation and wortmannin hardly interfered with
ERK signalling. We therefore conclude that in PC12 cells two
distinct pathways are involved in the regulation of eIF2B
activity.
Based on the present data and previous ¢ndings [7] it ap-
pears that both MEK- and PI 3-kinase-dependent pathways
are also involved in the inactivation of GSK-3 in response to
EGF or NGF. In CHO-T cells, the inactivation of GSK-3 is
associated with the dephosphorylation of Ser540 (Ser535 in
rat sequence), the GSK-3 phosphorylation site in eIF2Be.
Even though phosphorylation of Ser535 was detected in con-
trol PC12 cells, no dephosphorylation of Ser535 was observed
in response to EGF or NGF, which indicates that in PC12
cells the PI 3-kinase- or MEK-dependent regulation of the
activation of eIF2B by EGF or NGF is unlikely to involve
GSK-3. The phosphorylation state of the ‘priming site’,
Ser539, was also not a¡ected by EGF or NGF treatment.
Since both the identi¢ed phosphorylation sites in eIF2BO,
Ser535 and Ser539, are not regulated by EGF or NGF in
PC12 cells, it is not clear how the regulation of eIF2B activity
is linked to the MEK/ERK pathway. It may involve the (de)-
phosphorylation of another, as yet unidenti¢ed, site in eIF2Be
or in another subunit of the eIF2B heteropentameric complex.
Another important ¢nding of this study is that in PC12 cells
inactivation of GSK-3 in response to EGF or NGF occurs via
the MEK and PI 3-kinase pathways. Involvement of the
MEK pathway in the regulation of GSK-3 activity has been
suggested before. Transfection of a dominant negative mutant
of MEK in NIH/3T3 cells inhibited the EGF-induced decrease
in GSK-3 activity [19]. This may be mediated by p90rsk, since
early in vitro studies showed that GSK-3 can be inactivated
by p90rsk, which is activated by ERK [20^22].
The absence of dephosphorylation of Ser535, although
GSK-3 activity is decreased, is an interesting ¢nding. This
may re£ect the relatively small change in GSK-3 activity
(20^30%) in these cells : dephosphorylation of the GSK-3
site in eIF2Be was only previously shown in insulin-treated
Fig. 2. Activation of PKB by EGF or NGF is not inhibited by
PD98059. PC12 cells were serum-starved for 2 h and treated with
EGF for 3 min or with NGF for 5 min (previously reported to be
the peak times for PKB activity [16]) in the absence (control) or
presence (PD) of PD98059. All three isoforms of PKB were immu-
noprecipitated and a kinase assay was performed as described in
Section 2. The PKB activity in the control cells with no growth fac-
tor added was set at 100%. The graph shows an average of two in-
dependent experiments.
Fig. 3. Inactivation of GSK-3 by EGF or NGF is not a¡ected by
PD98059. A: The cells were serum-starved for 2 h and treated with
EGF (60 min) or NGF (90 min) in the absence (control) or pres-
ence (control+PD) of PD98059. After immunoprecipitation of GSK-
3, its activity was measured as described in Section 2. The graph
shows an average of six independent experiments (P6 0.005). The
error bars represent the standard error of the mean. B: Equal
amounts of cell lysate were analysed by SDS^PAGE and Western
blotting. Phosphorylation of Ser535, the GSK-3 site in eIF2BO, was
detected with a phospho-speci¢c antibody, phosphorylation of the
‘priming site’ Ser539 was detected with a phospho-speci¢c antibody
and the total amount of eIF2BO was detected with a polyclonal
antibody raised against eIF2BO (n = 6). eIF2BO indicates the total
amount of protein, peIF2BO indicates eIF2BO phosphorylated at
Ser535, and peIF2BO* indicates eIF2BO phosphorylated at Ser539.
3 : no addition, E: EGF, N: NGF, W: wortmannin (100 nM, 2 h).
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CHO-T cells, where the e¡ect on GSK-3 is much larger (60^
70% inactivation) [23,24]. However, it is also possible that
additional regulatory inputs are important in the activation
of eIF2B in PC12 cells under these conditions, e.g. the acti-
vation of a phosphatase. By analogy, in rat adipocytes, PDGF
and insulin each inactivate GSK-3, but only insulin a¡ects the
downstream target glycogen synthase. The di¡erence between
the two stimuli is that insulin also activates protein phospha-
tase 1, which is apparently required for activation of glycogen
synthase [25]. A similar situation may apply to the regulation
of eIF2B by the di¡erent stimuli in PC12 cells, but it remains
to be determined which phosphatase dephosphorylates Ser535
in eIF2BO. Furthermore, a role for GSK-3 in the regulation of
eIF2B has mostly been proposed for cells treated with insulin
[3,6,26].
From this paper and previous work, it has become clear
that the MEK/ERK pathway is important in the regulation
of general protein synthesis and of several translation initia-
tion factors. In PC12 cells, the EGF- or NGF-induced in-
crease in protein synthesis is blocked by the MEK inhibitor
PD98059, which coincides with inhibition of the phosphory-
lation of eIF4E, the formation of the eIF4F complex and the
activation of eIF2B.
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